Meropenem/vaborbactam: Phase III data

Top-line data from 374 patients with cUTI or acute pyelonephritis in the microbiologic mITT population of the double-blind, double-dummy, international Phase III TANGO 1 trial showed that 2 g/2 g Carbavance meropenem/vaborbactam

Read the full 326 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE